Eight IPOs and four SPACs went public this past week. One IPO postponed, UK-based biotech Gyroscope Therapeutics (VISN), citing market conditions. Filing activity maintained a comfortable pace/remained moderate, with seven IPOs and 10 SPACs...read more
Anebulo Pharmaceuticals, a Phase 2 biotech developing treatments for cannabinoid overdose and substance addiction, raised $21 million by offering 3 million shares at $7, within the range of $6 to $8. Insider 22NW had indicated on $5 million worth of shares...read more
Updated Monday, 5/3. 10 IPOs are expected to raise a total of $1.4 billion in the first week of May. The lineup is led by Jessica Alba’s highly-anticipated lifestyle brand, The Honest Company (HNST). The largest deal...read more
Anebulo Pharmaceuticals, a Phase 2 biotech developing treatments for cannabinoid overdose and substance addiction, announced terms for its IPO on Monday. The Lakeway, TX-based company plans to raise $21 million by offering 3 million shares at a price range...read more
US IPO Weekly Recap: Sacramento bank Five Star Bancorp finishes on top in an 8 IPO week
Eight IPOs and four SPACs went public this past week. One IPO postponed, UK-based biotech Gyroscope Therapeutics (VISN), citing market conditions. Filing activity maintained a comfortable pace/remained moderate, with seven IPOs and 10 SPACs...read more
Cannabinoid overdose biotech Anebulo Pharmaceuticals prices IPO at $7 midpoint
Anebulo Pharmaceuticals, a Phase 2 biotech developing treatments for cannabinoid overdose and substance addiction, raised $21 million by offering 3 million shares at $7, within the range of $6 to $8. Insider 22NW had indicated on $5 million worth of shares...read more
US IPO Week Ahead: May set to kick off with a 10 IPO week
Updated Monday, 5/3. 10 IPOs are expected to raise a total of $1.4 billion in the first week of May. The lineup is led by Jessica Alba’s highly-anticipated lifestyle brand, The Honest Company (HNST). The largest deal...read more
Cannabinoid overdose biotech Anebulo Pharmaceuticals sets terms for $21 million IPO
Anebulo Pharmaceuticals, a Phase 2 biotech developing treatments for cannabinoid overdose and substance addiction, announced terms for its IPO on Monday. The Lakeway, TX-based company plans to raise $21 million by offering 3 million shares at a price range...read more